These studies also establish the importance of MCL1, as well as BAK, as determinants of drug sensitivity in ovarian cancer and provide a potential rationale for further preclinical and possible clinical testing of MCL1 antagonists in ovarian cancer. This evidence concerns the gene MCL1 and ovarian carcinoma.